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Comments from the Norwegian Scientific Committee for Food Safety, Panel on 
Nutrition, dietetic products, Novel Food and Allergy (Panel 7) on the setting of 
maximum limits for vitamins and minerals in foods 
Tolerable Upper Intake Levels/Guidance Levels 
EFSA/SCF have established Tolerable Upper Intake Levels for several vitamins, minerals and 
trace elements. 
For those vitamins or minerals where no Tolerable Upper Intake Level has been established, 
the Expert Group on Vitamins and Minerals (EVM 2003), UK has suggested so called 
Guidance Levels (GL), and a Danish Expert group has suggested so called temporary 
Guidance Levels where no GLs have been established (Rasmussen et al. 2006)  The following 
is based on studies/evidence referred in the UK report and on the results from the Danish 
Expert group, but updated with new studies if such have been published the last couple of 
years.  It is important to note that GL values are derived for adults. Work has not started to 
find GL for children. 
Vitamin B1, thiamin.   
Case reports indicate that very high doses of thiamin (> 5000 mg) cause adverse effects like 
headache, nausea, irritability, insomnia, rapid pulse and weakness. These symptoms are 
relieved following cessation of treatment or reduction of dose. There have been a very small 
number (n = 4) of reported adverse effects following lower doses. No specific toxic effects of 
thiamine ingestion by humans have been identified. On the other hand, no large controlled 
human supplementation studies have been conducted.  
In a randomised, double-blind placebo-controlled study by Gokhale (Gokhale 1996), a daily 
oral dose of 100 mg thiamine hydrochloride was given  to 556 young females (12 – 21 y) for 
60 – 90 days. No adverse effects were reported. Based on this report, a level of 100 mg/day of 
supplemental thiamine (equivalent to 1.7 mg kg/kg bw/day supplemental thiamine for a 60 kg 
adult) would not be expected to result in adverse effects. This level could thus be considered a 
no-observed-adverse-effect-level (NOAEL). 
In the absence of an established lowest-observed-effect-level (LOAEL) and based on the 
above mentioned study among young girls, Panel 7 suggests a temporary Guidance Level of 
50 mg/day. This will allow for inter-individual differences in susceptibility considering that 
the group of young girls above is not representative of the total population. This is also in 
accordance with recommendations from the Danish Expert group and is also referred in the 
US IOM dose-response-assessment of thiamin 2000. They, however argue that supplements 
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containing up to 50 mg/day of thiamine are widely available without prescriptions, but that 
effects of intakes at this level or higher do not appear to have been studied systematically. 
 
 
Vitamin B2, riboflavin.  
There is insufficient data from human and animal studies to establish an Upper Level for 
riboflavin although the available data indicate that its toxicity is low. In a study from 1998 
(Schoenen et al. 1998), riboflavin (400 mg) and placebo were given to 55 patients with 
migraine in a randomized trial of 3 months duration. Using an intention-to-treat analysis, 
riboflavin was superior to placebo in reducing attack frequency (p = 0.005) and headache days 
(p = 0.012). Three minor adverse events occurred, two in the riboflavin group (diarrhoea and 
polyuria) and one in the placebo group (abdominal cramps). None was serious. If one allows 
for an uncertainly factor of 10, (because the number of participants was low), supplemental 
intakes of 40 mg riboflavin/day (equivalent to 0.67 mg kg/kg bw/day supplemental thiamine 
for a 60 kg adult) can be considered as a NOAEL. This is in addition to riboflavin provided 
from the diet.  
 
Panel 7 has not been able to find relevant publications from the last couple of years. Panel 7 
supports the UK Expert group in suggesting 40 mg/day as a Guidance Level for vitamin B2. 
 
 
Vitamin B12, cobalamin. 
Clinical studies have reported no adverse effects following administration of up to 6 mg/day 
of methylcobalamin for several weeks and up to 1 mg/day cyanocobalamin for several years. 
In a Swedish study from 1997  (Juhlin & Olsson 1997), 100 patients with vitiligo (loss of 
pigmentation in skin) were treated with oral folic acid and vitamin B12, the latter in doses of 2 
mg cyanocobalamin/day for up to 12 months. There were no reports of adverse effects.  
A 2 year intervention study on 628 older Japanese patients having had stroke was performed 
to test the protective effect of folate and vitamin B12 (Sato et al. 2005). Vitamin B12 was given 
in doses of 1500 µg mecobalamin. Twelve patients in the folate and vitamin B12 group 
experienced anorexia and nausea and one patient experienced itching. All symptoms subsided 
within a week of discontinuing the supplements. This intake level can be used for guidance 
purposes. It is equivalent to 0.025 mg/kg bw/day in a 60 kg adult. No uncertainty factor is 
needed because the number of individuals is in our opinion sufficient. However, it should be 
noted that the figure is based on patients that may not be representative of the whole 
population.  
 
The UK Expert group suggested 2 mg/day as a Guidance Level for vitamin B12 based on the 
study on vitiligo patients cited above. The Japanese study has been published later, but 
involves both folate and cobalamin. Further studies are needed to conclude, but based on the 
results from the Japanese study it cannot be ruled out that intake of cobalamin above 1500 µg/ 
day may represent a health risk. This should form the basis of a revised Guidance Level, and 
Panel 7 suggests 1500 µg as a Guidance Level for vitamin B12. 
 
 
Biotin 
Doses of 10 mg/day have been studied in a number of small clinical trials for therapeutic 
effects, without reported side effects. A supplemental dose of 9 mg/day was given to diabetics 
for up to 4 years with no associated adverse effects (Maebashi et al. 1993). Because all these 
studies have been small, and even fewer followed up long-term, an uncertainty factor of 10 
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for inter-individual variation is sensible to apply. Thus, for guidance purposes, a supplemental 
daily intake of 0.9 mg biotin (equivalent to 0.015 mg/kg bw/day in a 60 kg adult) would not 
be expected to produce adverse effects. Assuming a maximum intake of 0.066mg/day from 
food, an estimated total intake (from all sources) of 0.97 mg/day biotin would not be expected 
to result in any adverse effects.  
 
Panel 7 has not been able to find relevant publications from the last couple of years. Panel 7 
supports the UK Expert group in suggesting 0.9 mg/day as a Guidance Level for biotin. 
 
 
Pantothenic acid  
There are very few human studies available on the oral toxicity of pantothenic acid from 
controlled trials. In a randomized, double-blind, placebo-controlled study from 1980, 47 
arthritis patients were treated with calcium pantothenate (initially 500 mg/day, later 2000 
mg/day) for 8 weeks (General Practitioner Research Group 1980). Thirty-one patients in the 
intervention group completed the trial. The authors stated that no side effects were recorded in 
the patients on calcium pantothenate. Because of the low number of participants, an 
uncertainty factor of 10 should be applied to allow for inter-human variability. For guidance 
purposes only, a supplemental daily intake of 200 mg (equivalent to 3.3 mg/kg bw/day for a 
60 kg adult), in addition to that present in the diet, would not be expected to produce adverse 
effects. 
 
In a recent Japanese study on rats (Shibata et al. 2005), the animals were fed a diet containing 
0%, 0.0016% (control group), 1%, or 3% calcium pantothenate for 29 days. In the 3% 
addition group, enlargement of the testis, diarrhoea, and hair damage were observed, and the 
weight increase and food reduced compared to the control group. However, abnormality was 
not seen in the 1% addition group. The researchers conclude that the 3% level in the diet was 
the LOAEL and the 1% level was the NOAEL. Given as daily intake per kg bodyweight of 
rat, the NOAEL was around 1000 mg, while the LOAEL was around 3000 mg. With a safety 
factor of 100, the tolerable upper intake level would be around 10 mg/kg bw/day or 600 
mg/day (for a 60 kg adult). 
 
The UK Expert group suggests 200 mg/day as a Guidance Level for pantothenic acid. The 
Japanese study has been published later and could form the basis of a revised Guidance Level. 
It is at present not possible to conclude on which level is safe and appropriate, but the studies 
show that high intakes of pantothenic acid can give adverse effect, and that there is a need for 
setting of maximum limits. Further studies are needed to conclude on a GL or UL.   
 
 
Chromium (III)  
Overall, there are too few data from human or animal studies to derive a Safe Upper Level of 
chromium, probably mainly because trivalent chromium from the diet is poorly absorbed and 
thus the body is naturally protected. In isolated case reports, Cr picolinate supplementation 
has been said to cause adverse effects, such as anaemia, renal failure, liver dysfunction, and 
neuronal impairment. The same form of Cr has been associated with oxidative damage to 
DNA in rats and mutations and DNA fragmentation in cell cultures. Chromium interacts with 
iron by affecting its binding to transferrin, and has been shown to impair iron metabolism and 
storage. 
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A recently published study on rats (Bailey et al. 2006) tested large doses of  three forms of 
chromium commonly found in dietary supplements on developing rat foetuses. From 
gestation days (GD) 6-17, pregnant chromium-deficient (CD) mice were fed diets containing 
either 200 mg/kg Cr(picolinate)(3), 200 mg/kg CrCl(3), 174 mg/kg picolinic acid, or the diet 
only to determine if Cr(pic)(3), CrCl(3), or picolinic acid could cause developmental toxicity. 
Dams were sacrificed on GD 17, and their litters were examined for adverse effects. The 
incidence of bifurcated cervical arches was significantly increased in fetuses from the 
Cr(pic)(3) group as compared to the diet-only group. Fetuses in the picolinic acid-treated 
group had an incidence double that of the control group; however, this increase was not 
statistically significant. Fetuses in the CrCl(3) group did not differ from the controls in any 
variable examined. No maternal toxicity was observed in any of the treatment groups. 
Conclusions: High maternal oral exposures to chromium picolinate can cause morphological 
defects in developing offspring of mice. 
The doses in this study were very high. This was a clear effect level and can not be used to 
derive a NOAEL. The dosages correspond to 120 mg/day in a 60 kg adult.  
Another study on rats (Anderson et al. 1997), looking at the effect of 0 – 100 mg Cr /kg 
bw/day on outcomes like body weight, organ weights or blood variables, indicated that 15 
mg/kg bw/day of chromium (as Cr-cloride) was not associated with adverse effects in the rat. 
Based on this study, and again allowing for a total uncertainty factor of 100, 0.15 mg/kg 
bw/day, or 9 mg in a 60 kg person, would be expected to be without adverse health effects.  
In a very recently published study on rats (Scibior & Zaporowska 2007), 0.3 mg Cr/kg bw/day 
resulted in a significant decrease in kidney GSH concentration and GSH/GSSG ratio in both 
liver and kidney, indicating that Cr has pro-oxidative effects. The impact of this would be a 
reduced antioxidant defence in the body. If this study is taken as a starting point for 
establishing a NOAEL, and including the safety factor of 100, it would be equivalent to 0.003 
mg/kg bw/day in humans, or a total of 0.18 mg/day (= 180 µg/d). However, Panel 7 believes 
this study alone is too soft to be used as basis for establishing a GL. Panel 7 has chosen to use 
it to modify the UK GL suggestion. 
 
The study above, using GSH levels as an outcome measure, confirms that when no adverse 
effect levels have been found in earlier studies, it may be because we have not known what to 
look for. In general, all the divalent or trivalent ions that we classify as essential nutrients (Ca, 
Mg, Fe, Zn, Cu and Cr) have interactive effects on each others absorption, metabolism and/or 
excretion. They also have in common that the window from RDA to UL is rather narrow. 
There is no reason to believe this does not apply to chromium.  
 
The UK Expert group suggested 9 mg/day as a Guidance Level for trivalent chromium. The 
GHS-study has been published later, but the impact on health is uncertain. Further studies are 
needed to conclude, but based on the results from the GSH study it cannot be ruled out that an 
intake of chromium much lower than 9 mg/day for adults may represent a health risk. Panel 7 
therefore encourages a restrictive Guidance Level for chromium, and with the GSH study in 
mind thinks, for the time being, that the upper Guidance Level should be maximum 1 mg/day 
for an adult. 
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Vitamin K 
 
Panel 7 supports the UK Expert group in suggesting 1000 µg/day as a Guidance Level for 
vitamin K. 
 
 
Other vitamins and minerals/trace elements with potential health risk, but no 
established Upper Tolerable Intake Level from SCF/EFSA  
 
Iron 
Panel 7 supports JECFA and the Danish Expert group in suggesting 50 mg/day as a Guidance 
Level for iron. As is also concluded in the EFSA opinion on Tolerable Upper Intake Level for 
iron (2004), intake of 50-60 mg non-hem iron has caused gastrointestinal effects. 
 
Manganese 
Manganese and iron compete for absorption sites. Thus a high dietary level of one will reduce 
the absorption of the other. Panel 7 supports the UK Expert group in suggesting 4 mg/day as a 
Guidance Level for manganese.  
 
Vitamin C  
Panel 7 supports the Danish Expert group in suggesting 1000 mg/day as a Guidance Level for 
vitamin C. As is also concluded in the EFSA opinion on Tolerable Upper Intake Level for 
vitamin C (2004), intake of 1000 mg vitamin C can cause gastrointestinal effects. 
 
Beta-carotene 
Panel 7 supports the Danish Expert group in suggesting 5 mg/day as a temporary Guidance 
Level for beta-carotene. An intake of 5 mg/day represents the average dietary level for beta-
carotene, and a temporary GL at this level could therefore result in a zero allowance for 
fortification of foods with beta-carotene (depending on model for addition of nutrients to 
foods). Supplemental beta-carotene is contraindicated for use in heavy smokers (SCF opinion 
2000). Animal studies in ferrets indicate that beta-carotene per se affects cell differentiation 
and proliferation in the bronchus and substances in cigarette smoke enhance this effect (Wang 
et al. 1999). In a rather large study with 22071 male physicians, 12 years of supplementation 
with  50 mg beta-carotene on alternate days produced neither benefit nor harm in terms of the 
incidence of malignant neoplasms, cardiovascular disease or death from all causes 
(Hennekens et al. 1996). Although beta-carotene thus seems innocuous to others than 
smokers, excessive beta-carotene intake may affect population groups and target organs other 
than those presently investigated.  
 
General remark 
Several previous maximum limits for the different vitamins and minerals were lowered in the 
latest opinions from SCF and EFSA. New studies, e.g. on vitamin E and chromium, indicate 
that some of these Tolerable Upper Intake Levels should be revised and lowered even further. 
When evaluating the need for maximum limits for vitamins with insufficient human or animal 
data (as the above mentioned) this should be kept in mind.  
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